Search - tctmd.com

Displaying 61 - 80 of 148

Sort: Relevancy | Date

News Conference News ACC 2021

Wide Variation in TAVI Readmission Rates Among US Hospitals

L.A. McKeown

May 07, 2021

News Conference News ACC 2021

For Young Patients, Sex Gaps in MI Care Start in the Emergency Room

Caitlin E. Cox

May 06, 2021

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2020

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

Caitlin E. Cox

March 31, 2020

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation ACC 2020

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

Presenter: Mark Eisenberg

March 30, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

News Conference News ACC 2020

Hypertension-Related CV Deaths Surging Across the US

L.A. McKeown

March 24, 2020

News Conference News ACC 2020

Increased Physical Activity on Apple Watch Lowers BP

Yael L. Maxwell

March 23, 2020

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

Advertisement

Wide Variation in TAVI Readmission Rates Among US Hospitals

For Young Patients, Sex Gaps in MI Care Start in the Emergency Room

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

Evinacumab Cuts LDL Cholesterol in Homozygous FH

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Hypertension-Related CV Deaths Surging Across the US

Increased Physical Activity on Apple Watch Lowers BP

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content